ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Using Machine Learning to Predict the Prognosis of Cervical Cancer Patients with Lymph Node Metastasis: An Analysis Based on the SEER Database.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is one of the most common malignant tumors in women worldwide, and patients with lymph node metastasis have a poor prognosis. This study aimed to develop an effective machine learning model to predict the prognosis of these patients. Data from the SEER*Stat database (version: November 2021) was used, including 1016 female patients diagnosed with cervical cancer and lymph node metastasis from 2000 to 2020. Various machine learning models, including XGBoost, random forest, SVM, ANN, and the Cox proportional hazards model, were constructed and evaluated using metrics such as C-index, AUC, accuracy, and precision. Additionally, to validate model stability, a random sample of 200 patients from 8 registries between 1975 and 2019 was used as a validation set. XGBoost outperformed other models with an AUC of 0.787 in the validation set and C-index values of 0.900 and 0.773 for the training and testing sets, respectively. Cox regression analysis showed that surgery at the primary site significantly improved survival outcomes and reduced mortality. XGBoost demonstrated superior performance in predicting the prognosis of cervical cancer patients with lymph node metastasis, providing new support for personalized clinical management.
Indexed as
Identifiers
40195252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.